newsfilter
← Latest News
Business Wire·

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Japanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung cancer (NSCLC)